Gene Techno Science Co.,Ltd. Announces Non-Consolidated Earnings Results for the Year Ended March 31, 2018; Provides Earnings Guidance for the Fiscal Year Ending March 31, 2019
May 11, 2018
Share
Gene Techno Science Co.,Ltd. announced non-consolidated earnings results for the year ended March 31, 2018. For the year, the company reported net sales of JPY 1,059 million against JPY 1,089 million a year ago. Operating loss was JPY 913 million against JPY 1,184 million a year ago. Ordinary loss was JPY 903 million against JPY 1,176 million a year ago. Net loss was JPY 904 million or JPY 94.54 per share against JPY 1,224 million or JPY 137.01 per share a year ago. Negative return on equity was 29.9% against 63.5% a year ago. Cash flows used in operating activities was JPY 438 million against JPY 1,759 million a year ago. Net loss for the year before taxes was JPY 902 million against JPY 1,222 million a year ago. Purchase of fixed assets was JPY 252 million.
For the year ending March 31, 2019, the company expects net sales of JPY 1,060 million, Operating loss of JPY 1,180 million, Ordinary loss of JPY 1,180 million, net loss of JPY 1,182 million or JPY 123.54 per share.
Kidswell Bio Corp, formerly Gene Techno Science Co Ltd, is a Japan-based company mainly engaged in the development of biopharmaceuticals. The biosimilar business is engaged in the research, development and provision of filgrastim biosimilar products and pegfilgrastim biosimilar products for cancer, darbepoetin alfa biosimilar products for renal diseases, and ranibizumab biosimilar products for eye diseases. The new biopharmaceutical business is engaged in the research and development of anti-RAMP2 antibodies for cancer and eye diseases, as well as new antibodies. The new biotechnology business is engaged in the development of regenerative medicine products that utilize intracardiac stem cells for pediatric congenital heart diseases, and regenerative medicine products that utilize dental pulp stem cells for cleft lip and palate and intestinal ganglion cell deficiency diseases, as well as the joint research business with universities.
Gene Techno Science Co.,Ltd. Announces Non-Consolidated Earnings Results for the Year Ended March 31, 2018; Provides Earnings Guidance for the Fiscal Year Ending March 31, 2019